ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: 0.1% brimonidine tartrate ophthalmic solution
Drug: 0.01% bimatoprost ophthalmic solution
Drug: 0.2% hypromellose lubricant eye drops
Drug: latanoprost 0.005% ophthalmic solution

First Posted Date: 2012-02-02

Last Posted Date: 2013-12-04

Lead Sponsor: Allergan

Target Recruit Count: 137

Registration Number: NCT01525173

A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine

Phase 4

Completed

Conditions: Migraine Disorders

Interventions: Biological: onabotulinumtoxinA

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-06

Lead Sponsor: Allergan

Target Recruit Count: 716

Registration Number: NCT01516892

Locations: 🇺🇸
USC Neurology, Los Angeles, California, United States
🇺🇸
Ohio Clinical Research Partners, LLC, Canton, Ohio, United States
🇺🇸
Baylor Research Institute, Dallas, Texas, United States

and more 29 locations

Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthritis Knee Pain

Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Biological: botulinum toxin Type A
Drug: Normal Saline

First Posted Date: 2012-01-25

Last Posted Date: 2014-08-07

Lead Sponsor: Allergan

Target Recruit Count: 121

Registration Number: NCT01518257

Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women

Completed

Conditions: Health

Interventions: Other: No treatment

First Posted Date: 2012-01-25

Last Posted Date: 2019-05-01

Lead Sponsor: Allergan

Target Recruit Count: 179

Registration Number: NCT01518270

Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

Phase 2

Completed

Conditions: Macular Edema

Interventions: Drug: dexamethasone Intravitreal Implant
Drug: ranibizumab

First Posted Date: 2011-12-15

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 363

Registration Number: NCT01492400

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01% ophthalmic solution

First Posted Date: 2011-12-12

Last Posted Date: 2014-03-28

Lead Sponsor: Allergan

Target Recruit Count: 387

Registration Number: NCT01489670

Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis

Phase 2

Terminated

Conditions: Interstitial Cystitis

Interventions: Drug: Lidocaine Releasing Intravesical System - LiRIS®
Other: LiRIS Placebo
Procedure: Sham Cystoscopy Procedure

First Posted Date: 2011-11-21

Last Posted Date: 2015-09-21

Lead Sponsor: Allergan

Target Recruit Count: 104

Registration Number: NCT01475253

Locations: 🇺🇸
Women's Health Specialty Care, Farmington, Connecticut, United States
🇺🇸
Grove Hill Clinical Research, New Britain, Connecticut, United States
🇺🇸
Regional Urology LLC, Shreveport, Louisiana, United States

and more 26 locations

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Phase 4

Completed

Conditions: Conjunctivitis, Allergic

Interventions: Drug: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug: alcaftadine 0.25% ophthalmic solution
Drug: olopatadine 0.2% ophthalmic solution

First Posted Date: 2011-11-11

Last Posted Date: 2013-02-21

Lead Sponsor: Allergan

Target Recruit Count: 127

Registration Number: NCT01470118

Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MAP0004
Drug: IV DHE
Drug: Ketoconazole

First Posted Date: 2011-11-09

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 24

Registration Number: NCT01468558

Locations: 🇬🇧
Simbec Research Limited, Merthyr Tydfil, United Kingdom

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A
Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
Drug: Carboxymethylcellulose Based Lubricant Eye Drops
Drug: Carboxymethylcellulose Based Eye Drop Formulation B

First Posted Date: 2011-10-25

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 315

Registration Number: NCT01459588

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy